Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy increases bone mineral density
In plain terms: Does testosterone therapy strengthen bones?
Leans support Longevity & Aging 🔬 Includes disconfirming
Part of: 💊 Testosterone therapy (TRT)
RefutedContestedStrong support
consensus score 0.27
It increases bone density on scans, most clearly in the spine. But — importantly — no trial has shown it actually reduces broken bones (one 2026 analysis even found more fractures), so denser bone hasn't yet translated into fewer breaks. Oddly, the benefit comes mostly from estrogen your body makes from testosterone, not testosterone itself.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 3 contradict 0 tested null 4 mixed · 14 sources, 10 independent groups
What the evidence shows
Testosterone therapy increases bone mineral density, most clearly in the spine (trabecular bone) and less consistently at the hip/femoral neck — the strongest evidence is the Testosterone Trials' Bone Trial.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Di Chiano S, Diacinti D, Cipriani C, Diacinti D, Paoli ED, Pepe J, Lombardo F, Pallotti F 2026 · Endocrine | observational | contradicts | low | Prospective uncontrolled pilot, 14 AFAB transgender adults (mean age 24.1) starting testosterone, DXA at baseline and 12 months: 'All-site aBMD and TBS did not significantly change over time in the AFAB group.' A null on the directional 'increases BMD' claim = contradicts, but weak: n=14, no control, eugonadal young adults near peak bone mass rather than hypogonadal men (indirect population). The AMAB estrogen arm's lumbar BMD loss is off-object. |
| Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A 2005 · Clin Endocrinol (Oxf) | meta-analysis | supports | moderate | Random-effects meta-analysis of 29 RCTs, 1,083 middle-aged and ageing men (weighted mean age 64.5 years, mean serum testosterone 10.9 nmol/l): 'Testosterone improved bone mineral density (BMD) at the lumbar spine by +3.7% (CI: 1.0--6.4%) compared to placebo, but not at the femoral neck, and produced a consistent reduction in bone resorption markers (pooled effect size = -0.6 SMD, CI: -1.0 to -0.2).' Site-specific: spine yes, hip no. Read as supports rather than mixed because the significant spine result and the bone-turnover result point the same way and the femoral-neck result is a null at one site, not a reversal. THE MODERATOR IS PART OF THE FINDING: 'Sensitivity and meta-regression analysis revealed that the dose/type of T used, in particular the possibility of aromatization, explained the heterogeneity in findings observed on bone density and HDL-cholesterol among studies' - the BMD gain is conditional on an aromatizable preparation, consistent with the estrogen-mediated mechanism. DENOMINATOR: 1,083 / 29 RCTs spans all endpoints; how many trials measured lumbar or femoral-neck BMD is not stated and is the available text does not say. No fracture outcome is reported. Abstract-grade (not in the PMC open-access subset). |
| Zitzmann M, Soave A, Bier S 2026 · Maturitas | meta-analysis | supports | moderate | Narrative review, not evidence: 'This review distills contemporary evidence on the pathophysiology, clinical expression, diagnostic algorithms, and therapeutic armamentarium of male hypogonadism'. States therapy 'can reverse many of these perturbations' including bone density, no estimate. Review — zero weight. |
| De Silva NL, Papanikolaou N, Grossmann M, Antonio L, Quinton R, Anawalt BD, Jayasena CN 2024 · Lancet Diabetes Endocrinol | mechanism | supports | low | Review, not evidence: 'This Review discusses the pathogenesis and diagnosis of male hypogonadism and appraises the evidence'; states 'testosterone improves bone mineral density and insulin sensitivity in these men' but fracture evidence insufficient. Review — zero weight. |
| Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Strom BL 1999 · J Clin Endocrinol Metab | RCT | mixed | moderate | RCT (>65y): no overall group difference in lumbar BMD, but men with lowest baseline T gained (+5.9% vs +0.9%). |
| Junjie W, Dongsheng H, Lei S, Hongzhuo L, Changying S 2019 · Curr Pharm Des | meta-analysis | contradicts | low | Meta-analysis of 7 RCTs, 800 older men with low serum testosterone; BMD was the paper's primary outcome. 'T therapy did not significantly reverse the trend toward decreasing BMD in the spine, femoral neck, Ward's triangle and the whole body, with the exception of the trochanter and total hip', concluding 'T therapy is not effective in increasing BMD in older men.' Null at four sites, significant at two adjacent hip sub-regions. Note this inverts the usual pattern, in which the spine is the most responsive site. No pooled estimate, CI or heterogeneity reported in the available text (abstract only; full text paywalled). |
| Ng Tang Fui M, Hoermann R, Bracken K, Handelsman DJ, Inder WJ, Stuckey BGA, Yeap BB, Ghasem-Zadeh A, Robledo KP, Jesudason D, Zajac JD, Wittert GA, Grossmann M 2021 · Lancet Diabetes Endocrinol | RCT | supports | high | T4DM substudy: 2-yr TRT increased tibial/radial cortical vBMD (~3%) and lumbar/total-hip aBMD. |
| Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B, Zheng J 2016 · Exp Ther Med | meta-analysis | contradicts | moderate | BMD pool = 4 of the 16 RCTs, 743 participants (375 treated / 368 control): MD -0.01 g/cm2 (95% CI -0.03 to 0.02, P=0.60), null in every duration and route subgroup. Authors' own explanations: most included trials ran under 2 years against a 3-year osteoporosis window, participants were selected on androgen status rather than symptoms, and prior work found BMD gains only where baseline testosterone was below the reference range. |
| Kafel H, Basaria S 2026 · Curr Osteoporos Rep | meta-analysis | mixed | moderate | Narrative review (Curr Osteoporos Rep 'Purpose of Review'): aims to 'summarize data from seminal trials of testosterone therapy and its effects on bone density and fracture risk'. Reports robust BMD gains in organic hypogonadism and 'modest increases in BMD (mainly vertebral BMD)' in age-related low T. No pooling. Review — zero weight. |
| Anagnostis P, Divaris E, Zidrou M, Kassi E, Tournis S 2026 · Endocrine | meta-analysis | mixed | moderate | Fracture meta (2 RCTs, n=2711): higher overall clinical-fracture risk (RR 1.55) but not major osteoporotic fractures (RR 0.62 ns) - BMD gains not translating to fewer fractures. |
| de Silva NL, Hyams E, Grant B, Dixit P, Bassi R, Bassett P, Comninos AN, Jayasena CN 2025 · Clin Endocrinol (Oxf) | observational | supports | low | SR/meta (hypogonadotropic hypogonadism, n=625): low BMD improves with hormone treatment, often incomplete normalization. |
| Dias JP, Melvin D, Simonsick EM, Carlson O, Shardell MD, Ferrucci L, Chia CW, Basaria S, Egan JM 2016 · J Clin Endocrinol Metab | RCT | supports | low | RCT (65-82y): TRT improved primary outcome lumbar spine BMD at 12 months. |
| Boeri L, Masterson T, Antonio L, Corona G, Khera M, Salonia A, Mulhall JP 2026 · Eur Urol | meta-analysis | supports | moderate | Narrative review, not evidence: 'A nonsystematic literature review was conducted to identify relevant studies on the diagnosis and treatment of TD.' States 'Evidence indicates that TTh improves sexual function, body composition, metabolic profile, and bone mineral density' with no estimate. Review — zero weight. |
| Buratto J, Kirk B, Phu S, Vogrin S, Duque G 2023 · Arch Endocrinol Metab | meta-analysis | mixed | moderate | Meta 16 RCTs: increased hip BMD at 6 months; effects unclear for lumbar spine and at 12 months. |
| Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW 2016 · J Clin Invest | mechanism | supports | moderate | Dose-ranging mechanistic RCT: estrogen (from T aromatization), not testosterone per se, is the primary driver of BMD maintenance. |
| Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R 2008 · Aging Male | RCT | supports | low | RCT (elderly): TRT increased lumbar spine BMD significantly; no femoral-neck change. |
| He JH, Bennett WL, Ma J, Oyeka CP, Kodali LS, Srialluri N, Gisinger T, Woodward M, Michos ED, Johnson KC, Vaidya D 2026 · The Journal of clinical endocrinology and metabolism | RCT | mixed | high | Look AHEAD ancillary analysis: in men, an intensive-lifestyle-intervention-associated 11% INCREASE in total testosterone mediated a DECLINE in hip BMD (-1.18 mg/cm2, 95% CI -2.68 to -0.13) over 4 years. |
| Arcand PH, Peresuh SJ, Confessore J, Testa EJ, Quinn M, Singh M, Avellino GJ, Daniels AH, Arcand MA 2026 · JSES Reviews, Reports, and Techniques | observational | contradicts | moderate | Large matched retrospective claims-database cohort (n=335,753 pairs): the paper's only measured endpoint is 2-year proximal humerus fracture incidence, not bone density — 'Patients administered TRT demonstrated a higher incidence of PHF compared to the control cohort (0.029% vs. 0.005%, P < .001)... adjusted odds ratio 3.14; 95% confidence interval: 1.84-5.59.' BMD-raising is cited only as background from other literature ('Testosterone replacement therapy (TRT) is used to treat hypogonadism and is associated with increased bone mineral density'), never measured here; the paper's own discussion treats density and fracture as decoupled ('Though TRT improves BMD, bone strength is not solely determined by density'), and no serum testosterone, SHBG, or BMD/imaging data were collected. |
| Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM 2017 · JAMA Intern Med | RCT | supports | high | T-Trials Bone Trial (>=65y): spine trabecular vBMD +6.8% treatment effect and greater estimated bone strength vs placebo. |
| Bouloux PM, Legros JJ, Elbers JM, Geurts TB, Kaspers MJ, Meehan AG, Meuleman EJ, Study 43203 Investigators 2013 · J Clin Endocrinol Metab | RCT | supports | moderate | Dose-ranging RCT (n=322): oral testosterone undecanoate increased spine/hip/trochanter BMD dose-dependently. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.